Guggenheim Capital LLC Sells 670 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Guggenheim Capital LLC cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,201 shares of the company’s stock after selling 670 shares during the period. Guggenheim Capital LLC owned approximately 0.10% of CRISPR Therapeutics worth $3,432,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Sanctuary Advisors LLC lifted its position in CRISPR Therapeutics by 17.8% during the third quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock valued at $398,000 after purchasing an additional 1,258 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter worth $40,000. Franklin Resources Inc. increased its holdings in shares of CRISPR Therapeutics by 12.7% in the 3rd quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock worth $339,000 after buying an additional 800 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of CRISPR Therapeutics by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company’s stock valued at $4,913,000 after buying an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 0.0 %

CRSP opened at $37.77 on Friday. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of -8.64 and a beta of 1.85. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88. The business’s fifty day simple moving average is $40.93 and its 200-day simple moving average is $43.76.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,381 shares of company stock valued at $1,608,243. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on CRSP. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Truist Financial boosted their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. Citigroup dropped their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.